Literature DB >> 17352366

Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease.

Jose S Pulido1, Joseph P McConnell, Ryan J Lennon, Sandra C Bryant, Lisa M Peterson, Peter B Berger, Virend Somers, W Edward Highsmith.   

Abstract

OBJECTIVE: To determine whether either of the gene variants associated with age-related macular degeneration is associated with coronary artery disease (CAD). PATIENTS AND METHODS: This study consisted of 493 patients who underwent clinically indicated coronary angiography between June 1, 1998, and January 1, 1999. The Y402H variant of the complement factor H (CFH) gene and the A69S variant of the LOC387715 gene locus were examined by restriction fragment length polymorphism. Multiple logistic regression models were used to assess the association of CFH and LOC gene variants with CAD. Covariates with well-established associations with CAD were also evaluated.
RESULTS: Seventy patients (14%) were homozygous for the histidine variant (HH) of CFH, 237 (48%) were heterozygous for the histidine variant (HY), and 186 (38%) were homozygous for the tyrosine variant (YY). Three hundred eight patients (62%) were homozygous for the alanine allele of LOC387715, 170 (34%) were heterozygous for Ala and Ser alleles, and 15 (3%) were homozygous for the serine variant. The overall association of the CFH genotype with CAD was not statistically significant (P=.08). However, some evidence (P=-.046) suggested that CAD was increased for the HH genotype compared to the homozygous wild-type YY genotype (odds ratio, 1.95; 95% confidence interval, 1.01-3.76). Male sex, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and age were other variables that demonstrated significant associations with CAD. The overall effect of the LOC genotype was not statistically significant (P=-.06). Heterozygosity for the serine variant was (P=-.02) associated with the absence of CAD vs the AS genotype (odds ratio, 0.59; confidence interval, 0.38-0.91; P=-.02).
CONCLUSION: The CFH genotype may have an independent association with CAD, although our evidence did not show statistical significance. Controlling for known risk factors, the age-related macular degeneration-associated HH variant appears to be associated with CAD. The LOC387715 gene may also play a role in CAD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352366     DOI: 10.4065/82.3.301

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

1.  Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms.

Authors:  Digna R Velez Edwards; Paul Gallins; Monica Polk; Juan Ayala-Haedo; Stephen G Schwartz; Jaclyn L Kovach; Kylee Spencer; Gaofeng Wang; Anita Agarwal; Eric A Postel; Jonathan L Haines; Margaret Pericak-Vance; William K Scott
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

2.  Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Antonio B Fernandez; Tien Y Wong; Ronald Klein; Dorothea Collins; Gregory Burke; Mary Frances Cotch; Barbara Klein; Mehran M Sadeghi; Jersey Chen
Journal:  Ophthalmology       Date:  2011-12-23       Impact factor: 12.079

3.  ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.

Authors:  Alicia Valverde-Megías; Silvia Veganzones-de-Castro; Juan Donate-López; Maria Luisa Maestro-de-Las-Casas; Alicia Megías-Fresno; Julián García-Feijoo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-25       Impact factor: 3.117

4.  Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis.

Authors:  Hai-Feng Zhang; Jing-Feng Wang; Yan Wang; Li-Guang Zhu; Lei Lei
Journal:  Mol Biol Rep       Date:  2010-02-03       Impact factor: 2.316

Review 5.  Complement factor H: using atomic resolution structure to illuminate disease mechanisms.

Authors:  Paul N Barlow; Gregory S Hageman; Susan M Lea
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

6.  Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype.

Authors:  Reecha Sofat; Juan P Casas; Andrew R Webster; Alan C Bird; Samantha S Mann; John R W Yates; Anthony T Moore; Tiina Sepp; Valentina Cipriani; Catey Bunce; Jane C Khan; Humma Shahid; Anand Swaroop; Gonçalo Abecasis; Kari E H Branham; Sepideh Zareparsi; Arthur A Bergen; Caroline C W Klaver; Dominique C Baas; Kang Zhang; Yuhong Chen; Daniel Gibbs; Bernhard H F Weber; Claudia N Keilhauer; Lars G Fritsche; Andrew Lotery; Angela J Cree; Helen L Griffiths; Shomi S Bhattacharya; Li L Chen; Sharon A Jenkins; Tunde Peto; Mark Lathrop; Thierry Leveillard; Michael B Gorin; Daniel E Weeks; Maria Carolina Ortube; Robert E Ferrell; Johanna Jakobsdottir; Yvette P Conley; Mati Rahu; Johan H Seland; Gisele Soubrane; Fotis Topouzis; Jesus Vioque; Laura Tomazzoli; Ian Young; John Whittaker; Usha Chakravarthy; Paulus T V M de Jong; Liam Smeeth; Astrid Fletcher; Aroon D Hingorani
Journal:  Int J Epidemiol       Date:  2012-01-13       Impact factor: 7.196

7.  Age-related macular degeneration and progression of coronary artery calcium: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Antonio B Fernandez; Kevin D Ballard; Tien Y Wong; Mengye Guo; Robyn L McClelland; Gregory Burke; Mary Frances Cotch; Barbara Klein; Matthew Allison; Ronald Klein
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

8.  An ecological correlation study of late age-related macular degeneration and the complement factor H Y402H polymorphism.

Authors:  Bareng A S Nonyane; Dorothea Nitsch; John C Whittaker; Reecha Sofat; Liam Smeeth; Usha Chakravarthy; Astrid E Fletcher
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-30       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.